Cell cycle status may play an important role in directing patient therapy. We therefore determined the cell cycle status of leukaemic cells by immunophenotypic analysis of bone marrow trephine biopsies from 181 patients with acute myeloid leukaemia (AML) and correlated the results with biological features and clinical outcome. There was considerable heterogeneity between patients. The presenting white cell count significantly correlated with the proportion of non-quiescent cells (P < 0Á0001), of cycling cells beyond G 1 (P < 0Á0001) and the speed of cycling (P < 0Á0001). Profiles in acute promyelocytic leukaemia (APL) differed from non-APL and were consistent with more differentiated cells with reduced proliferative potential, but no significant differences were observed between non-APL cytogenetic risk groups. NPM1 mutations but not FLT3 internal tandem duplication (FLT3 ITD ) were significantly associated with a higher proportion of cells beyond G 1 (P = 0Á002) and faster speed of cycling (P = 0Á003). Resistance to standard cytosine arabinoside and daunorubicin induction chemotherapy was significantly related to a slower speed of cycling (P = 0Á0002), as was a higher relapse rate (P = 0Á05), but not with the proportion of non-quiescent cells or actively cycling cells. These results show a link between the cycling speed of AML cells and the response to chemotherapy, and help to identify a group with a very poor prognosis.
Introduction
Knowledge of cell cycle status may play an important role in directing patient therapy. In a variety of solid tumours, it is indicative of which patients are likely to respond to cell cycle phase-specific agents, and may be predictive of the long-term outcome . However, in acute myeloid leukaemia (AML), although the main therapeutic agents are cytosine arabinoside (Ara-C), which is cell cycle S phase-specific, and topoisomerase II-inhibiting anthracyclines that have greater toxicity in rapidly proliferating cells, the results of studies addressing the relationship between the cell cycle status of leukaemic blast cells and clinical response have been inconsistent (Hiddemann et al, 1982a; Preisler et al, 1984; Raza et al, 1990 Raza et al, , 1991 Vidriales et al, 1995; Braess et al, 2001 ). This may partly reflect the different techniques used but is most likely to represent the different types of samples used. It has been shown that fewer leukaemic cells in the blood are cycling compared to the bone marrow (Mauer & Fisher, 1962; Hiddemann et al, 1982b) , and using direct immunophenotyping we demonstrated that nearly all of the leukaemic blasts in the peripheral blood (PB) were arrested in G 1 , with only 1% beyond G 1 , compared to 24% in the bone marrow trephine (BMT) samples (Sellar et al, 2016) . Furthermore, only 6% of cells were beyond G 1 in matched bone marrow aspirate (BMA) samples, considerably less than in the BMTs due to variable dilution with bloodderived blasts.
As the number of blasts in a BMA sample that are bloodderived is likely to depend on both the volume of the sample taken and the presenting white cell count (WCC), this suggests that in patients with a higher proliferative rate leading research paper to a higher blast cell count in the PB, the degree of contamination of the BMA with PB is likely to be greater and, paradoxically, the cycling rate observed in the BMA sample would therefore be spuriously lower. For accurate assessment of cell cycle status, it is therefore essential to analyse BMT samples.
Another factor that may influence cell cycle status is the molecular heterogeneity of AML that is now apparent . This is highly relevant to current therapy strategies as some molecular abnormalities such as internal tandem duplications in the FLT3 gene (FLT3 ITD ) and nucleophosmin gene mutations (NPM1 MUT ) are highly predictive of outcome and used to risk-stratify patient management (Dohner et al, 2017; O'Donnell et al, 2017) . Both are also associated with a higher presenting WCC (Dohner et al, 2005; Gale et al, 2008) . The relationship between proliferative status and response to therapy has been reported to be dependent on the cytogenetic risk group (Braess et al, 2001) and, more recently, Behbehani et al (2015) have reported that the proportion of AML early progenitor cells that are in cell cycle is lower in cases with a FLT3 ITD . However, BMAs were used for these studies.
In order to address these issues, we have used immunohistochemistry of trephine biopsies from AML patients to assess cell cycle status and the proportion of cells undergoing apoptosis, and investigated the relationship between these parameters, the cytogenetic risk group, molecular subtype as defined by FLT3 and NPM1 mutational status, as well as clinical outcome. The data indicate that the proportion of cells beyond G 1 and the speed of cell cycling are predictive of outcome.
Materials and methods

Patient cohort
All patients studied presented with newly diagnosed AML to University College London Hospital (UCLH) between January 2003 and December 2011 and had a diagnostic biopsy performed prior to treatment. Local research ethics approval for the study was obtained from the Joint University College London (UCL)/UCLH Committees on the Ethics of Human Research, and informed patient consent was obtained in accordance with the Declaration of Helsinki. Patient records were reviewed to define patient demographics, details of the therapy received and response to treatment, including induction death (ID), achievement of complete remission (CR), cumulative incidence of relapse (CIR), time to relapse and overall survival (OS). Response definitions are given in the Supporting Information.
Molecular analysis
Molecular analysis was performed on DNA available from the UCL tissue bank or extracted from stored BMA smears using the Qiagen DNeasy Blood and Tissue Kit (Qiagen, Manchester, UK). FLT3 and NPM1 genotype were determined as previously described (Gale et al, 2008) .
Immunohistochemistry (IHC)
Serial sections of formalin-fixed paraffin-embedded BMTs were processed and stained as previously described (Sellar et al, 2016) using antibodies to Mcm2 to assess non-quiescent cells regardless of whether or not they were actively cycling (positive in G 1 , S, G 2 and M but not G 0 ), MIB-1 (equivalent to Ki67) for actively proliferating cells (positive in a proportion of cells in G 1 , and cells in S, G 2 and M but not G 0 ) and geminin for cycling cells that have progressed beyond G 1 (positive in S, G 2 and M but not G 1 and G 0 ). In addition, the sections were stained for cleaved caspase 3 (Cell Signaling Technology, Hitchin, UK) to assess the proportion of cells undergoing apoptosis (Suzuki et al, 2012) . The proportion of non-quiescent cells that are proliferating (MIB-1/ Mcm2 ratio) is inversely related to the number of cells arrested in G 1 , and the geminin/MIB-1 ratio is an indicator of the average speed of the cell cycle, with the time in S phase being relatively constant and the time in G 1 accounting for most of the variability of the cell cycle duration (Wharton et al, 2004) . Tonsil tissue containing both glandular and epithelial components was processed at the same time, as a positive control. The number of leukaemic cells positive for each of the antibodies was determined using the Ariol automated scanning microscope and image analysis system (Turashvili et al, 2009 ), counting at least 1000 cells per sample (see Supporting Information). Results were expressed as the labelling index (LI), i.e. the number of positive cells as a proportion of the total cells after excluding most lymphoid and erythroid cells.
Statistical analysis
Full details of the statistical analysis are provided in the Supporting Information.
Results
Patient characteristics and treatment
In total, 187 AML patients newly diagnosed between January 2003 and December 2011 and with available pre-treatment trephine biopsies were identified. Six were subsequently excluded: five had inadequate material for further immunohistochemistry and one had a coincident B cell malignancy. Median age of the remaining 181 patients was 55 years (range, 13-86); 55% were male (Table I ). Overall, 83% had de novo AML; the remaining patients had secondary disease due to a preceding haematological disorder (10%) or prior chemotherapy (7%) administered at least 2 years before the current presentation. Fifteen patients (8%) had acute promyelocytic leukaemia (APL), and 166 had non-APL patients received an alternative intensive regimen and 17 received a non-intensive chemotherapy regimen, most commonly subcutaneous low-dose Ara-C. Twenty-nine patients (16%) received an allogeneic transplant in first CR. Five patients received no treatment and one was lost to follow-up.
Outcome of patients receiving intensive induction therapy
The CR rate after one cycle of induction therapy was 100% in the APL patients. In the non-APL patients treated with Ara-C and an anthracycline the CR rate was 66% (92%, 73% and 39% respectively in the favourable-, intermediate-and adverse-risk cytogenetic groups). Seventeen patients (12%) died during induction therapy and 31 (22%) were alive but not in CR. After further cycle(s) of induction therapy, the CR rate increased to 71%. OS at 3 years was 100% for APL and 41% for non-APL patients (P = 0Á0004). In the cytogenetic risk groups, OS was 76%, 41% and 26%, respectively (P = 0Á001). Patients aged <60 years had a significantly longer survival than those aged ≥60 years (median, 1478 days vs. 282 days respectively, P < 0Á0001).
Cell cycle analysis and cleaved caspase staining
Cell cycle profiling of all 181 patients indicated that the majority of leukaemic blasts in the BMTs were not quiescent (median Mcm2 LI, 81%), and approximately 40% of the non-quiescent cells were MIB-1 positive and therefore actively cycling (Table II) . The median geminin LI was 17%, and approximately half of the actively cycling cells had progressed beyond G 1 (median geminin/MIB-1 ratio, 0Á51). There was, however, considerable heterogeneity within the cell cycle profile, with relatively wide interquartile and overall ranges (Table II) . Very few blasts were undergoing apoptosis (median cleaved caspase LI, 3%).
Relationship to biological risk factors
There was no correlation between any of the cell cycle parameters and patient age at presentation, but cleaved caspase staining was positively correlated with increasing age (r = 0Á3, P = 0Á0001). This relationship was maintained when either APL or secondary AML was excluded (r = 0Á3, P = 0Á0003 for both analyses). The presenting WCC was significantly correlated with the proportion of non-quiescent cells (r = 0Á4, P < 0Á0001) but not the proportion of actively cycling cells (for MIB-1 LI, r = 0Á1, P = 0Á06). It did, however, correlate with the proportion of cycling cells beyond G 1 and the speed of cell cycle in cycling cells (for geminin LI, r = 0Á4, P < 0Á0001; geminin/MIB-1 ratio, r = 0Á3, P < 0Á0001). It was also inversely correlated with the proportion of apoptotic cells (for cleaved caspase LI, total cohort, r = À0Á2, P = 0Á002; non-APL patients, r = À0Á3, P < 0Á0001). These results suggest that a higher WCC typically occurs in those cases with faster cell cycle progression rates and lower levels of apoptosis. No significant differences in cell cycle parameters or the proportion of apoptotic cells were observed between de novo and secondary AML patients (data not shown).
Relationship to French-American-British classification (FAB) type
Patients with APL had significantly fewer non-quiescent cells, actively cycling cells and cells in S/G 2 /M compared to other FAB types, and a greater proportion of cells in a G 1 -arrested state (Fig 1; Table II) . They also had a significantly lower median geminin/MIB-1 ratio, implying a longer average duration of G 1 in the cycling cells. There was no significant association between other FAB types and cell cycle markers (data not shown). The APL patients also had a significantly lower proportion of cleaved caspase labelled cells, with no differences observed between other FAB types.
Relationship to cytogenetic risk groups
Differences in cell cycle parameters between the cytogenetic risk groups in the non-APL patients were not statistically significant (Table II) . However, the proportion of apoptotic cells was slightly, but significantly, higher in the poorer cytogenetic risk patients (respectively 1Á9%, 2Á8% and 3Á4% in the favourable-, intermediate-and adverse-risk cytogenetic groups, P = 0Á03). vs. 85%, P = 0Á03). Although the proportion of actively cycling cells was also higher, the difference was not significant (median MIB-1 LI, 40% vs. 34%, P = 0Á4). However, the proportion of cycling cells that had progressed beyond G 1 was significantly higher in the NPM1 MUT cases (median geminin LI, 24% vs. 15%, P = 0Á002), as was the geminin/ MIB-1 ratio (0Á68 vs. 0Á40, P = 0Á003) (Fig 2) . 92% vs. 84%, P = 0Á03) but the proportion of actively cycling cells and of cells in S/G 2 /M was similar (median MIB-1 LI, 36% vs. 36%, P = 0Á77; median geminin LI, 21% vs. 19%; P = 0Á5). The geminin/MIB-1 ratio was also not significantly different (0Á48 vs. 0Á52, P = 0Á8). When the NPM1 MUT and NPM1 WT populations were analysed separately, there was again no significant impact of the FLT3 ITD status (P = 0Á41 and 0Á82 with regard to the geminin/MIB-1 ratio in the NPM1 MUT and NPM1 WT populations respectively). Inspection of the geminin/MIB-1 ratio in all non-APL cases (Fig 1E) and in the intermediate-risk disease category (Fig 2B) suggested that there were two distinct subpopulations. An exploratory analysis was therefore carried out, comparing clinical, morphological, cytogenetic and limited genotype features between those patients with higher and lower geminin/MIB-1 ratios. No significant differences were found. The proportion of cells positive for cleaved caspase was not influenced by either the NPM1 or FLT3 genotype (P = 0Á2 and P = 0Á4 respectively).
Relationship between cell cycle status, cleaved caspase staining and response to therapy
For the 140 non-APL patients that received intensive induction therapy, 66% achieved CR after one cycle of chemotherapy, and neither the proportion of non-quiescent cells nor of actively cycling cells differed between those who did or did not achieve CR (Mcm2 LI, 83% vs. 75%, P = 0Á2; MIB-1 LI, 34% vs. 37%, P = 0Á9). Nevertheless, patients who achieved an early remission did have a significantly higher proportion of cells beyond G 1 (geminin LI, 19% vs. 13%, P = 0Á004) and geminin/MIB-1 ratio (0Á54 vs. 0Á41, P = 0Á0002), and this relationship was still statistically significant when CR at any time was considered (71% of the cohort: geminin LI, 19% vs. 12%, P = 0Á02; geminin/MIB-1 ratio, 0Á52 vs. 0Á42, P = 0Á02). However, further inspection of the response data revealed that the CR rates were confounded by an excess of IDs in those patients with the higher geminin/MIB-1 ratios. In multivariate analysis of the total cohort considering biological, cytogenetic and molecular characteristics, the factors predicting for ID were WCC (P = 0Á01) and age (P = 0Á02), with the impact of the geminin/MIB-1 ratio not achieving significance (P = 0Á1). If IDs were excluded, the factors significantly predicting for attainment of CR after one cycle of therapy were the presence of an NPM1 mutation (P = 0Á001) and the geminin/MIB-1 ratio (P = 0Á01).
When the patients were grouped according to quartiles of the geminin/MIB-1 ratio, it was apparent that there was an association between this ratio and the achievement of CR after one cycle of therapy, with the highest CR rate (74%) in the quartile with the highest geminin/MIB-1 ratio (Q1: median, 0Á81) and the lowest CR rate (54%) in those with the lowest ratio (Q4: median, 0Á30), although this difference did not reach significance (P = 0Á08 across all quartiles) (Table III) . IDs were, however, significantly higher in Q1 (26%) and lower in Q4 (6%; P = 0Á01 across all groups), which is probably due to the higher presenting WCC in Q1 patients, a known risk factor for ID and an independent adverse risk factor for ID in this study. In fact, of the nine IDs in Q1 patients, seven had a WCC above the median value of 56 9 10 9 /l for this quartile. Furthermore, six of these seven patients were over the age of 60 years, and four of the nine patients with early deaths had secondary leukaemia. When the induction mortality as well as the CR rate was taken into account, there was a highly significant relationship between resistant disease and the geminin/MIB-1 ratio. In Q1, every patient who was alive after the first course of induction therapy was in CR compared to only 58% in Q4 (P = 0Á0002) (Table III) . Considering best response at any time, the values for resistant disease were 0% in Q1 and 24% in Q4 patients (P = 0Á02). It is notable that the incidence of NPM1 mutations was much higher in Q1 than in Q4 and it is not possible to clearly separate the impact on chemo-resistance of the cell cycle profile per se and the NPM1 mutational status. The number of patients who Table III . Patient characteristics and outcome according to quartiles of the geminin/MIB-1 ratio in non-APL patients receiving intensive induction therapy. APL, acute promyelocytic leukaemia; CIR, cumulative incidence of relapse; CR, complete remission; FLT3 ITD , internal tandem duplication of the FLT3 gene; LI, labelling index; NPM1 MUT , nucleophosmin gene mutation; OS, overall survival; Q1, quartile with the highest geminin/MIB-1 ratio; Q4, quartile with the lowest geminin/MIB-1 ratio; WCC, white cell count.
Cell Cycle Analysis in AML ª 2018 John Wiley & Sons Ltd received a consolidation allograft in first remission was similar in each quartile (Table III) . After censoring patients at the time of transplant, the relapse rate was higher in Q4 (P = 0Á04). Furthermore, five out of six patients in Q4 who received and survived an allograft subsequently relapsed.
Relationship between geminin/MIB-1 ratio and long-term outcome
The CIR and OS at 3 years in the non-APL patients who received intensive induction therapy were 47% and 41% respectively. The CIR varied significantly between the different geminin/MIB-1 ratio quartiles; it was highest (73%) in Q4 patients with the lowest geminin/MIB-1 ratio (P = 0Á01) (Table III) (Fig 3A) . Although the difference in OS between the quartiles was not significant, this was again confounded by the higher rate of ID in the Q1 patients. In view of the high relapse rate in the Q4 patients, an exploratory landmark analysis was performed from the time at which patients received their second cycle of intensive chemotherapy, comparing Q4 (n = 31) with Q1-3 patients (n = 83). The difference in survival between these groups was borderline significant (P = 0Á05) (Hazard ratio by logrank analysis, 1Á65; 95% confidence intervals, 0Á996-3Á126). Median survival was 472 days vs. 1346 days in Q4 and Q1-3 respectively (Fig 3B) .
Discussion
The results presented here on the cell cycle status of leukaemic cells and its relationship to outcome in a cohort of 181 AML patients are from a single centre, but the characteristics of the cohort with regard to age, cytogenetics, mutational status and response to treatment are similar to other reported series. An important feature of the study was that the cell cycle analysis of the leukaemic cells was determined from BMTs. This was essential in order to avoid the impact on the results of blood contamination of BMAs (Mauer & Fisher, 1962; Hiddemann et al, 1982b; Sellar et al, 2016) .
The results showed that only a minority of bone marrow leukaemic cells were in G 0 , which is similar to other malignancies where this parameter has been assessed (Dudderidge et al, 2005; Obermann et al, 2005; Kulkarni et al, 2007; Kayes et al, 2009; Loddo et al, 2009) . There was also a relatively high proportion of actively cycling cells (approximately onethird of leukaemic cells), similarly comparable to other malignancies, although considerably less than in Burkitt lymphoma where nearly all the cells are actively cycling (Obermann et al, 2005) . A striking feature of the current findings, however, was that those AML cells that were actively cycling were doing so rapidly (geminin/MIB-1 ratio, 0Á53), which is about twice the value observed in ovarian and penile cancer, and nearly three times that in breast cancer (Kulkarni et al, 2007; Kayes et al, 2009; Loddo et al, 2009) . This speed of cycling may therefore contribute to the observed sensitivity of AML cells to the cell cycle phase-specific agents that have been the backbone of standard therapy for several decades.
Nevertheless, there was considerable heterogeneity in the cell cycle profile observed between patient samples and this highlighted several important factors. Firstly, a more proliferative profile with fewer quiescent cells, more cells in S/G 2 /M, and a faster cycling rate was associated with a higher presenting WCC, as was a lower percentage of apoptotic cells. Secondly, APL patients formed a distinct subgroup, with more cells in G 0 , fewer cells actively cycling and in S/G 2 /M, and a greater proportion of cells likely to be in a G 1 -arrested state than non-APL patients. They also had a lower geminin/MIB-1 ratio, implying a slower cell cycle time, and a lower cleaved caspase LI. This data is in accord with the fact that most of the cells in APL are differentiated to a relatively late maturational stage, by which time the proliferative potential is markedly reduced. No differences were observed between other FAB types. Thirdly, the cytogenetic risk group did not seem to impact on the cell cycle parameters, despite the fact that core binding factor leukaemias (good-risk cytogenetics) are known to be highly sensitive to high dose Ara-C. The presence of an NPM1 mutation was, however, associated with more quickly cycling cells. This accords with the fact that NPM1 mutations are associated with a higher presenting WCC (Dohner et al, 2005; Gale et al, 2008) . Unexpectedly, a similar relationship was not observed for FLT3 ITD , which is counterintuitive in that an activating mutation in a growth factor receptor would be expected to induce more rapid proliferation. It is possible that the major impact of a FLT3 ITD is on the more primitive leukaemic progenitor cells and not the bulk leukaemic cells, although recent studies have suggested that the more primitive AML progenitors in FLT3 ITD AML have a lower proliferative fraction than the same phenotypic subpopulation in other forms of AML (Behbehani et al, 2015) . It is possible that other mutations may have an impact on the cell cycle profile of the leukaemic blast cells, but a much larger cohort of patients with trephine biopsies carried out at diagnosis will be required to ascertain this. In spite of the general sensitivity of AML cells to cell cycle phase-specific agents, it was noteworthy that the proportion of actively cycling cells did not significantly correlate with the CR rate. Nevertheless, the speed of cell cycling as assessed by the geminin/MIB-1 ratio was inversely related to chemoresistance to Ara-C plus anthracycline combination chemotherapy, and although it was most significant after the initial cycle of intensive induction therapy, it was still apparent when best response at any time was considered. The impact on CR rate was much less apparent than on chemoresistance, and this was largely due to the higher treatmentrelated mortality in those patients with the most rapidly proliferative disease. The latter have, on average, a much higher presenting WCC, which is a known major risk factor for early death (Walter et al, 2011; Othus et al, 2014) .
The rate of relapse was significantly higher in the quartile with the slowest cell cycling time than in the other quartiles and this was not obviously influenced by the use of consolidation with allogeneic transplantation in first CR. The higher rate of relapse in Q4 did not translate into a significantly lower OS, which was again likely to be due in part to the confounding effect of the increased treatment-related deaths in the cohort with the fastest cell cycling time. This finding has interesting biological implications. Although the attainment of CR is a reflection of the properties of the bulk of the leukaemic cells, relapse is thought to originate from the leukaemic stem cells (LSC), which have a more primitive phenotype and are thought to proliferate more slowly than the bulk of cells (Saito et al, 2010) . Nonetheless, our data suggests that proliferation kinetics in the bulk population may be a surrogate for the chemosensitivity of the LSCs, probably indicating that in those cases where the bulk cells are proliferating more quickly so too are the LSCs, albeit at a lower level than in the bulk population, and vice-versa. This may be testable by multi-parameter immunophenotypic analysis of AML progenitor cell populations using flow cytometry or mass cytometry on single cell suspensions made from BMTs, but the small size of BMT samples generally available for study after removal of the portion required for diagnostic purposes will make this challenging. The ability to predict the likelihood of chemo-resistance to standard therapy and to ascertain which patients are most at risk of relapse, may be of clinical value by suggesting which patients might benefit from the early introduction of non-cell cycle-specific agents and high dose therapy consolidation.
